...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial
【24h】

Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial

机译：关节内注射阿达木单抗治疗中度至重度膝关节骨关节炎的疗效和安全性：一项开放标签的随机对照试验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

ObjectiveTo evaluate the efficacy and safety of adalimumab (ADA) versus hyaluronic acid (HA) by intra-articular injection for moderate to severe knee osteoarthritis.MethodsFifty-six consecutive patients with moderate to severe knee osteoarthritis were randomly allocated to either the ADA group or HA group. On day 0, patients in the ADA group received 10?mg of ADA by intra-articular injection, while those in the HA group received 25?mg of HA. All patients received celecoxib at 200?mg/day for 4 weeks. The pain visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Patient Global Assessment (PGA), and Physician Global Assessment (PhGA) scores were assessed.ResultsAt baseline, the pain VAS, WOMAC, PGA, and PhGA scores were similar between the two groups. The decrease in the pain VAS score, WOMAC pain score, WOMAC physical function score, and WOMAC total score from baseline to week 4 were greater in the ADA than HA group. A greater decrease in the PGA and PhGA scores from baseline to week 4 was noted in the ADA than HA group. No difference in adverse events was observed between the two groups.ConclusionADA by intra-articular injection was effective and tolerated for moderate to severe knee osteoarthritis.
机译：目的评估关节内注射阿达木单抗（ADA）与透明质酸（HA）的疗效和安全性。方法将56例连续的中重度膝关节骨关节炎患者随机分为ADA组或HA组。在第0天，ADA组患者通过关节内注射接受10μmgADA，而HA组中的患者接受25μmgHA。所有患者均接受200毫克/天的塞来昔布治疗4周。评估了疼痛视觉模拟量表（VAS），西安大略省和麦克马斯特大学的骨关节炎指数（WOMAC），患者总体评估（PGA）和医师全局评估（PhGA）得分。结果在基线时，疼痛VAS，WOMAC，PGA和两组之间的PhGA得分相似。从基线到第4周，疼痛VAS评分，WOMAC疼痛评分，WOMAC身体功能评分和WOMAC总评分的降低在ADA组中高于HA组。与基线组相比，ADA中从基线到第4周的PGA和PhGA得分下降幅度更大。两组之间未观察到不良事件的差异。结论关节内注射ADA对中至重度膝关节骨关节炎有效且可耐受。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号